A pivotal phase 3 trial reported that Lucerastat, an oral therapy, showed efficacy signals in patients with Fabry disease. The results detail clinical endpoints and safety observations that support further regulatory engagement. Given Fabry’s unmet needs and the rarity of oral disease‑modifying options, the data could influence treatment paradigms and commercial positioning if confirmatory steps and regulatory dialogues proceed favorably.